Iovance Biotherapeutics, Inc. (IOVA)

Iovance Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	196.51	163.08	115.69	114.89	231.73	78.23
Short-Term Investments	116.94	133.9	208.09	164.98	240.11	426.18
Cash & Short-Term Investments	313.44	296.98	323.78	279.87	471.85	504.41
Cash Growth	-12.86%	-8.28%	15.69%	-40.69%	-6.46%	-19.86%
Accounts Receivable	81.76	82.45	69.34	0.15	-	-
Inventory	58.38	51.68	51.52	10.37	-	-
Other Current Assets	12.93	11.58	12.38	17.46	7.27	3.55
Total Current Assets	466.5	442.69	457.02	307.85	479.12	507.96
Net Property, Plant & Equipment	175.78	177.01	164.28	176.55	178.25	169.92
Other Intangible Assets	269.1	279.32	282.4	229.26	-	-
Long-Term Investments	-	-	-	-	-	91.59
Other Long-Term Assets	14.28	14.15	6.73	66.7	6.62	7.87
Total Assets	925.67	913.17	910.43	780.35	663.98	777.33
Accounts Payable	37.45	22.16	27.51	33.12	26.6	27.38
Accrued Expenses	88.07	111.16	81.94	69.41	52.3	56.77
Short-Term Debt	1	1	-	-	-	-
Current Portion of Leases	2.9	4.04	12.9	7.78	12.59	5.06
Total Current Liabilities	129.42	138.36	122.34	110.31	91.49	89.2
Long-Term Debt	-	-	1	1	1	1
Long-Term Leases	43.88	44.4	44.37	67.09	71.86	65.47
Other Long-Term Liabilities	30.61	31.83	32.32	17.35	-	-
Total Long-Term Liabilities	74.49	76.23	77.68	85.43	72.86	66.47
Total Liabilities	203.91	214.59	200.02	195.74	164.34	155.67
Preferred Stock	0	0	0	0	0	0
Common Stock	0.02	0.02	0.01	0.01	0.01	0.01
Additional Paid-in Capital	3,564	3,458	3,096	2,594	2,069	1,795
Accumulated Other Comprehensive Income	12.65	16.44	-1.05	2.53	-0.9	-0.6
Retained Earnings	-	-	-	-2,012	-1,568	-1,172
Shareholders' Equity	3,576	3,474	3,095	584.61	499.64	621.66
Total Liabilities & Equity	925.67	913.17	910.43	780.35	663.98	777.33
Total Debt	47.78	49.44	58.26	75.86	85.45	71.53
Net Cash (Debt)	265.67	247.54	265.52	204.01	386.4	432.88
Net Cash Growth	7.32%	-6.77%	30.15%	-47.20%	-10.74%	-25.08%
Net Cash Per Share	0.70	0.69	0.92	0.87	2.43	2.82
Book Value	3,576	3,474	3,095	584.61	499.64	621.66
Book Value Per Share	9.39	9.72	10.68	2.49	3.14	4.05
Tangible Book Value	3,307	3,195	2,813	355.36	499.64	621.66
Tangible Book Value Per Share	8.68	8.94	9.70	1.51	3.14	4.05

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q